Mobile

A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with C...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001601-16

A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with Chronic Hepatitis C

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To investigate the safety and tolerability of multiple oral doses of GS-9450 in subjects with chronic hepatitis C (HCV).

Critère d'inclusion

  • Chronic hepatitis C

Liens